Skip to main content

Table 4 Mutations acquired by patients failing second line treatment

From: Outcome of patients on second line antiretroviral therapy under programmatic condition in India

Patient ID Gene Bank
Accession No.
Duration of second line treatment (months) Adherence during 2nd line treatment Subtype Major
PI mutation
Minor PI mutation NRTI mutation NNRTI mutation GSS score Etravirine sensitivity score
SL-1 KJ933454 46 >95 % C M46I, I47A, I50IL, I84V A71V M41L, D67N, K70R, L74IL, M184V, T215Y, K219Q K103N, K238KN 0 0
SL-2 KJ933455 13 >95 % C NONE NONE M41L, D67N, M184V, T215F, K219W Y181V, G190A 1.25 4
SL-3 KJ933456 23 >95 % C M46I, N88S L24I, Q58E, A71V M41L, K65R, K70T, M184V A98G, K101E, G190A 0 3
SL-4 KJ933457 9 >95 % C NONE NONE M184V K101E, G190A 2 2
SL-5 KJ933458 20 >95 % C M46I L23IL D67N, V75M, M184V Y181C 1.25 2.5
SL-6 KJ933459 24 >95 % C None K20I, L90LW None V108IV, Y181C, H221Y 3 2.5
SL-9 KJ933461 25 <95 % C M46I, I50L, V82A L33FL, A71AV, G73S, N83DN M41L, D67N, V75M, M184V, L210W, T215Y, K219N A98G, K103N 0 1
SL-11 KJ933463 9 >95 % C M46I, N88NS K20IT, E35DEG, A71AT, T74S M41L, M184V, L210W, T215Y, K219KN K101H, Y181CFIS, G190A 0 7.5
SL-12 KJ933464 14 >95 % C NONE K20KT, G73S M41L, D67E, V75M, M184V, L210W, T215Y V90I, V108I, Y181C 0.5 3.5
SL-13 KJ933465 10 >95 % A1C I84IV L23I, A71V M41L, D67N, L74I, V75M, M184V, L210W, T215Y, K219N A98G, K103N, G190 0 2
SL-14 KJ933466 9 <95 % C None None None None 3 0
SL-15 KJ933467 20 >95 % C NONE NONE M41L, D67N, V75M, M184V, T215Y, K219N V90I, K103N 1.25 1
SL-16 KJ933468 20 >95 % C NONE T74S M41L, K70R, L74I, M184V, T215F, K219W V106M, V108I, Y181C, F227L 1.25 2.5
SL-19 KJ933469 12 <95 % C NONE NONE NONE K101E 3 1
SL-20 KJ933470 36 >95 % C M46I NONE M41L, D67N, T69D, V75M, M184V, L210W, T215Y A98G, K101EK, V108I, V179IT, G190A, F227L 0.75 4
SL-21 KJ933471 18 <95 % C N88S L10F, K20T, Q58E D67N, T69D, K70R, M184V, T215F, K219Q K101E, Y181C 0.25 3.5